✨ Free AI Report
Bicara Therapeutics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Bicara Therapeutics Inc.
Company Research

Bicara Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody combining an EGFR-directed ...

Analyst-debate audio for Bicara Therapeutics Inc.

AskCyborg analysts argue the bull and bear cases for Bicara Therapeutics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Clinical-stage bifunctional oncology biotech with encouraging Phase 1b efficacy signals, significant cash runway from recent IPO,...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology (Solid Tumors)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Bicara Therapeutics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Bicara Therapeutics Inc. Overview

Pro stress-test →

Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody combining an EGFR-directed monoclonal antibody with a TGF-beta-binding domain for treating solid tumors. The company recently went public in September 2024 and is advancing its pipeline toward pivotal trials.

Strategic Profile

Pro stress-test →

Bicara's development strategy centers on ficerafusp alfa for solid tumors. Key clinical focus areas include FORTIFI-HN01 (a Phase 2/3 trial in head and neck cancer) with enrollment expected to support an interim analysis in mid-2027 for potential accelerated filing, plus expansion cohorts in colorectal cancer. The dual-targeting approach addresses both tumor-intrinsic and immune-suppressive mechanisms in hard-to-treat cancers.

Competitive Landscape

Pro stress-test →

Bicara competes in the oncology biopharmaceutical space against larger companies developing immune-oncology and targeted therapies. Key competitors include established players like Merck (Keytruda), Bristol Myers Squibb, and Regeneron in checkpoint inhibition, as well as emerging biotech focused on combination approaches. Bicara's bifunctional platform differentiates through dual EGFR/TGF-beta targeting rather than single-mechanism approaches.

Industry Context

Bicara Therapeutics Inc. operates in Biopharmaceutical - Oncology (Solid Tumors).

Key facts

Founded: 2018 · Headquarters: Boston, Massachusetts · Revenue: $0 · Market cap: $919M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Bicara Therapeutics Inc..

  • Ficerafusp alfa targets dual pathways: EGFR (tumor proliferation) and TGF-beta (immunosuppression), potentially differentiating from single-mechanism competitors
  • FORTIFI-HN01 Phase 2/3 trial expects substantial enrollment by end-2026 with interim analysis mid-2027 supporting accelerated filing potential
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Presented Phase 1b expansion data showing 57% ORR in HPV-negative head and neck cancer with ficerafusp alfa 750mg plus pembrolizumab
  • January 2026CEO presentation at J.P. Morgan Healthcare Conference
  • +1 moreTrack every material event for Bicara Therapeutics Inc. as it happens. Explore monitoring →
Get alerted when Bicara Therapeutics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pembrolizumab (Keytruda)PD-1 checkpoint inhibitor for multiple cancer types→OpdivoPD-1/PD-L1 checkpoint inhibitor in oncology→REGN2810 (Cemiplimab)PD-1 inhibitor for advanced cancers→

Compare Bicara Therapeutics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Bicara Therapeutics Inc. operates in Biopharmaceutical - Oncology (Solid Tumors). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology (Solid Tumors) research →
NEW · MCP server

Ask your AI assistant about Bicara Therapeutics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Bicara Therapeutics Inc. and its top competitor on Cyborg Score”
“What did Bicara Therapeutics Inc. do this quarter?”
“Is Bicara Therapeutics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Bicara Therapeutics Inc. do?+
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody combining an EGFR-directed ...
What is Bicara Therapeutics Inc.'s Cyborg Score?+
Bicara Therapeutics Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Bicara Therapeutics Inc.'s main competitors?+
Named competitors include Pembrolizumab (Keytruda), Opdivo, REGN2810 (Cemiplimab). The full competitive landscape is in the AskCyborg report.
How can I get the full Bicara Therapeutics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Bicara Therapeutics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Bicara Therapeutics Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Oncology (Solid Tumors) research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Bicara Therapeutics Inc.